Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2020.7932
Abstract: This phase 3 randomized clinical trial compares the clinical efficacy of margetuximab vs trastuzumab, each with chemotherapy, in patients with pretreated ERBB2-positive advanced breast cancer. read more here.
Keywords: pretreated erbb2; erbb2 positive; efficacy margetuximab; margetuximab trastuzumab ... See more keywords
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2019 at "Gastric Cancer"
DOI: 10.1007/s10120-019-00973-5
Abstract: BackgroundTrastuzumab with cisplatin and fluoropyrimidines improves overall survival (OS) in patients with HER2-positive advanced gastric cancer (AGC). S-1 plus oxaliplatin (SOX) is one of the standard regimens for HER2-negative AGC in Japan. However, few studies… read more here.
Keywords: patients her2; her2 positive; gastric cancer; agc ... See more keywords
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02043-2
Abstract: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status… read more here.
Keywords: egfr; tki; positive advanced; progression ... See more keywords
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
Sign Up to like & getrecommendations! Published in 2019 at "Breast"
DOI: 10.1016/j.breast.2019.05.011
Abstract: OBJECTIVES Common therapies for HER2-positive advanced breast cancer (ABC) are associated with heterogeneity in prognosis and treatment benefit. Prognostic models of survival outcomes with ado-trastuzumab-emtansine (T-DM1) have not been evaluated. MATERIAL AND METHODS A pre-treatment… read more here.
Keywords: prognostic groups; treatment; her2 positive; patients initiating ... See more keywords
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.10.027
Abstract: OBJECTIVES In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase… read more here.
Keywords: t790m positive; platinum pemetrexed; egfr mutation; positive advanced ... See more keywords
Cost‐effectiveness analysis of fulvestrant versus anastrozole as first‐line treatment for hormone receptor‐positive advanced breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Cancer Care"
DOI: 10.1111/ecc.12733
Abstract: Abstract Although recent studies demonstrated that fulvestrant is superior to anastrozole as first‐line treatment for hormone receptor (HR)‐positive advanced breast cancer, the cost‐effectiveness of fulvestrant versus anastrozole remained uncertain. Thus, the current study aimed to… read more here.
Keywords: first line; positive advanced; anastrozole first; cancer ... See more keywords
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0809
Abstract: Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma.… read more here.
Keywords: advanced melanoma; cobimetinib plus; plus vemurafenib; brafv600 mutation ... See more keywords
Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
Sign Up to like & getrecommendations! Published in 2019 at "Oncology"
DOI: 10.1159/000497276
Abstract: Background: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence. The combination of T-DM1… read more here.
Keywords: metastatic breast; positive advanced; her2 positive; breast cancer ... See more keywords
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Sign Up to like & getrecommendations! Published in 2020 at "Acta Haematologica"
DOI: 10.1159/000506346
Abstract: Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in… read more here.
Keywords: positive advanced; chromosome positive; philadelphia chromosome; myeloid ... See more keywords
The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221074973
Abstract: Introduction At present, the prognosis of HER2-positive advanced gastric cancer is extremely poor, and some patients fail to benefit from first-line Herceptin treatment, thus facing difficulties in choosing second-line drugs. Case Report Here, we report… read more here.
Keywords: positive advanced; her2 positive; advanced gastric; gastric cancer ... See more keywords
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.1025
Abstract: 1025Background: Pertuzumab (P) provided overall and progression-free survival (PFS) benefits in HER2-positive metastatic breast cancer (MBC) in the CLEOPATRA study as a first-line therapy. However, long-term administration of intravenous docetaxel at a dose of 75… read more here.
Keywords: her2 positive; pertuzumab; positive advanced; breast cancer ... See more keywords